Evidence map›Paper›PMID 35016216›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Potential Effects of the Coronavirus Disease 2019 (COVID-19) Pandemic on Human Immunodeficiency Virus (HIV) Transmission: A Modeling Study in 32 US Cities.

Anthony Fojo, Emma Wallengren, Melissa Schnure, David W Dowdy, Maunank Shah, Parastu Kasaie

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trends and Disruptions in Antiretroviral Treatment Enrollment in Haiti, 2018-2024.The American journal of tropical medicine and hygiene · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Impacts of COVID-19 on HIV/AIDS-Related Services in California.Journal of the International Association of Providers of AIDS Care
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anthony FojoDivision of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Emma WallengrenDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Melissa SchnureDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
David W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Maunank ShahDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Parastu KasaieDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Ending the HIV Epidemic in Rural America (EHE-RA): Local Interventions, Co-Epidemics, and Social DeterminantsR01MD018539 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI Anthony Todd Fojo · 2022 to 2026
$4.0M
Optimizing outcomes at the intersection of HIV and mental health: Prediction, precision medicine, and population healthK08MH118094 · NIMH · JOHNS HOPKINS UNIVERSITY · PI FOJO, ANTHONY TODD · 2018 to 2022
$953k
Projecting the Epidemiologic and Economic Impact of HIV Prevention Efforts in the Context of Other Sexually Transmitted InfectionsK01AI138853 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KASAIE, PARASTU · 2019 to 2023
$591k
NIAID NIH HHS K01 AI138853NIAID NIH HHS P30 AI094189NIAID NIH HHS T32 AI102623NIMHD NIH HHS R01 MD018539NIMH NIH HHS K08 MH118094
6 · The paper itself

Abstract

backgroundThe degree to which the 2019 novel coronavirus disease (COVID-19) pandemic will affect the US human immunodeficiency virus (HIV) epidemic is unclear.

methodsWe used the Johns Hopkins Epidemiologic and Economic Model to project HIV infections from 2020 to 2025 in 32 US metropolitan statistical areas (MSAs). We sampled a range of effects of the pandemic on sexual transmission (0-50% reduction), viral suppression among people with HIV (0-40% reduction), HIV testing (0-50% reduction), and pre-exposure prophylaxis use (0-30% reduction), and indexed reductions over time to Google Community Mobility Reports.

resultsSimulations projected reported diagnoses would drop in 2020 and rebound in 2021 or 2022, regardless of underlying incidence. If sexual transmission normalized by July 2021 and HIV care normalized by January 2022, we projected 1161 (1%) more infections from 2020 to 2025 across all 32 cities than if COVID-19 had not occurred. Among "optimistic" simulations in which sexual transmission was sharply reduced and viral suppression was maintained we projected 8% lower incidence (95% credible interval: 14% lower to no change). Among "pessimistic" simulations where sexual transmission was largely unchanged but viral suppression fell, we projected 11% higher incidence (1-21% higher). MSA-specific projections are available at www.jheem.org?covid.

conclusionsThe effects of COVID-19 on HIV transmission remain uncertain and differ between cities. Reported diagnoses of HIV in 2020-2021 are likely to correlate poorly with underlying incidence. Minimizing disruptions to HIV care is critical to mitigating negative effects of the COVID-19 pandemic on HIV transmission.

Indexed as

COVID-19HIV InfectionsCitiesHIVHumansPandemicsCOVID-19dynamic HIV transmission modelHIVinfectious disease transmission

Identifiers

PMID35016216
PMCPMC8755375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.